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Abstract 
Numerous approaches are being developed to promote post-natal muscle growth based on 
attenuating Myostatin/Activin signalling for clinical uses such as the treatment neuromuscular 
diseases, cancer cachexia and sarcopenia. However there have been concerns about the effects 
of inhibiting Activin on tissues other than skeletal muscle. We intraperitoneally injected mice 
with the Activin ligand trap, sActRIIB, in young, adult and a progeric mouse model. Treatment 
at any stage in the life of the mouse rapidly increased muscle mass. However at all stages of life 
the treatment decreased the weights of the testis. Not only were the testis smaller, but they 
contained fewer sperm compared to untreated mice. We found that the hypertrophic muscle 
phenotype was lost after the cessation of sActRIIB treatment but abnormal testis phenotype 
persisted. In summary, attenuation of Myostatin/Activin signalling inhibited testis development. 
Future use of molecules based on a similar mode of action to promote muscle growth should be 
carefully profiled for adverse side-effects on the testis. However the effectiveness of sActRIIB 
as a modulator of Activin function provides a possible therapeutic strategy to alleviate testicular 
seminoma development. 
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 Skeletal muscle is an adaptable tissue capable of 
changing its mass and composition to meet the 
physiological needs of the human body.1 The amount of 
protein present in any organ is controlled by the rate of 
its synthesis and breakdown and it has been estimated 
that, in humans, it has a turnover rate of 5.7g/kg/day,2 
with skeletal muscle proteins having an average half-life 
of only 20 days3 Therefore, the regulation of skeletal 
muscle protein content is highly dynamic, and any 
failures in the mechanisms responsible may manifest in 
muscle loss or atrophy.  A variety of clinically relevant 
factors have been described that lead to muscle loss 
including genetic mutations (e.g. Duchenne Muscular 
Dystrophy-DMD), diseases in non-skeletal muscles that 
produce muscle wasting molecules (as in cancer 
cachexia) and age-related muscle wasting (sarcopenia).  
Given that muscle wasting is such a common feature of 
human life, it is hardly surprising that great efforts have 
been made to understand muscle loss with a view of 
attenuating or reversing this process. Many different 
molecules have received interest from a therapeutic 
perspective over the last few decades including anabolic 
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steroids,4 growth hormones,5 and IGF-1.6 However all of 
these are associated with adverse side effects. 
The landscape of muscle growth promoting molecules 
was revolutionized following the discovery of 
Myostatin.7 In a ground-breaking study, the group of Se-
Jin Lee showed that this member of the TGF-β family of 
secreted signalling proteins was predominantly 
expressed by skeletal muscle during embryogenesis and 
its deletion in mouse (the Mstn-/- line) led to a huge 
increase in muscle mass as a consequence of muscle 
hyperplasia and fiber hypertrophy.7 Thereafter mutations 
in the Myostatin (Mstn) gene have been found in a 
number of mammalian species including one case in 
humans all of which manifest with muscle hypertrophy.8 
Thereafter a number of strategies have been developed to 
attenuate the activity of Myostatin during post-natal life 
in-order to promote muscle growth for therapeutic uses. 
These include: antibodies and a variety of proteins 
(including Follistatin,9 GASP-1,10 LTBP-311) that bind to 
Myostatin and prevent it from functioning normally, and 
propeptide regions that re-associate with Myostatin.12 
Alternative anti-Myostatin strategies have been 
developed based on ligand-receptor interactions. 
Myostatin and related TGF ligands such as Activin 
exert their action by binding to a heterotetrameric 
receptor complex comprised of two Type I and two Type 
II receptors on their target cells. Myostatin/Activin 
signalling is mediated by either ALK4 or ALK7 and 
ACVR2A or ACVR2B (henceforth ActRIIA or ActRIIB, 
respectively).13 This knowledge has been exploited to 
develop ligand blocking antibodies to ActRIIB which 
have been shown to promote robust muscle 
hypertrophy.14 In addition, we and others developed a 
stabilized peptide containing the ligand binding domain 
of ActRIIB (hereafter referred to as sActRIIB) which also 
promotes skeletal muscle growth.15 The latter two 
strategies are particularly attractive in terms of muscle 
wasting therapies since it has been shown that Activin as 
well as Myostatin signal through the ActRIIB receptor to 
inhibit muscle growth; sActRIIB promotes muscle 
growth in the Mstn-/- mice.16 However studies have 
shown the sActRIIB binds a number of forms of Activin 
as well as GDF11 and BMPs 2,7, 9 and 10.17-20 
The broad ligand-binding spectrum of sActRIIB raises 
the concern that although it is able to promote muscle 
growth, it may interfere with other cellular processes. 
Indeed, the use of a sActRIIB molecule in primates was 
shown to increase pancreas and spleen weights as well as 
interfering with glucose homeostasis.21 
In this study we examined the impact of sActRIIB on the 
development of the testis and sperm as both processes 
have been shown to be regulated by Activin. The 
mammalian testis is a complex organ composed of 
several cell types, organized in structurally distinct 
domains that undertake its two main functions. The 
seminiferous tubule is where spermatogenesis occurs and 
between these convoluted tubules are the interstitial cells, 
blood vessels and the sites of male hormone production. 
Within the seminiferous tubule, surrounded by a 
basement membrane are Sertoli cells (SC). These are 
somatic cells that interact with the spermatogenic cells 
and act as support cells for spermatogenesis. SC 
proliferate and differentiate in the postnatal testis and the 
maximum number of SC per testis is established by day 
15 in mice. Spermatogenesis is closely linked to SC 
function. At the basal surface of the seminiferous tubule 
between the SCs reside spermatogonial stem cells which 
gives rise to spermatogonia. Spermatogonia undergo a 
series of mitotic divisions that lead to spermatogonial 
renewal and differentiation into Type A and then Type B 
spermatogonia. These then undergo mitosis and 
differentiation to produce primary or preleptotene 
spermatocytes. Importantly, these diploid cells traverse 
through the blood-testis barrier (BTB), a tight junction 
between two adjacent SCs to reach the adluminal 
compartment. The BTB physically prevent the 
movement of molecules between the circulation and the 
adluminal compartment, isolating the adluminal 
compartment and sperm from the rest of the periphery. 
This transit is a prerequisite for the secondary or 
leptotene spermatocyte to enter meiotic division 
producing haploid round spermatids which undergo a 
series of differentiation steps to ultimately generate 
spermatozoa  
TGF ligand signalling is a crucial regulator of 
spermatogenesis. Among these factors, Activin is known 
to play a role at least in early stages of postnatal testicular 
development in mice. Evidence supports a role of Activin 
in determining Sertoli cell numbers and spermatogonial 
maturation.22,23 Activin expression in the testis peaks in 
postnatal week 1 and is diminished after the 
establishment of the full complement of SC numbers by 
the end of week 2.24 A measurement of total Activin 
protein per testis however demonstrates a trough around 
day 20 and then increased expression from day 30 
onwards. Moreover, in-situ hybridization data localizes 
InhBA and InhBB transcripts in SC, spermatogonium as 
well as spermatocytes in the adult.24 There is also 
evidence that Activin is produced in peritubular myoid 
cells.23 These findings support a role for Activin in 
testicular function beyond SC number regulation in the 
early postnatal testis. Indeed, mice with a deletion of 
ActRIIA show a significant impairment of testicular 
growth and spermatogenesis underscoring the 
importance of TGF ligands that bind to this receptor in 
testicular development and function.8,25 
Since the sActRIIB ligand-trap is known to bind 
Activin,26 and that Activin action is crucial for testicular 
development and function we sought to investigate 
whether increase in muscle mass induced by sActRIIB is 
accompanied by changes in testicular biology. We have 
investigated whether there is a developmental window 
(age of mice) within which these effects are restricted and 
whether they are reversible over periods of non-
intervention. Finally, to compare and contrast the 
testicular effect of inhibition of Activin or Myostatin we 
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have also investigated the testicular phenotype of Mstn 
null mice. We show that sActRIIB treatment decreases 
testis size at any stage of the life of mice. Furthermore, 
we show that the testis phenotype persists longer than 
muscle hypertrophy following the withdrawal of 
sActRIIB treatment. 
Materials and Methods 
Ethical approval 
The experiments were performed under a United 
Kingdom Home Office project license, in agreement with 
the Animals (Scientific Procedures) Act 1986. The 
University of Reading Animal Care and Ethical Review 
Committee approved all procedures. Animals were 
humanely sacrificed via Schedule 1 killing.  
Animal maintenance 
All mice used were bred and maintained in accordance to 
the Animals (Scientific Procedures) Act 1986 (UK) and 
approved by the Biological Resources Unit of University 
of Reading. Post-natal Myostatin/Activin block was 
induced via intraperitoneal (IP) injection with 10mg/kg 
of sActRIIB-Fc (hereafter sActRIIB) twice weekly. The 
age of initial injection varied among different studies. 
CD1 mice were obtained from Jackson laboratories and 
bred for pups. 10mg/kg sActRIIB-Fc was injected at P17 
until P37 in all CD1 mice studies with three collection 
points; P37, P56 and P180. Mstn+/- and Mstn-/- tissues 
were obtained from Versailles Saint-Quentin-en-
Yvelines University at 7.5 months of age. ERCC1 ∆/- 
mice were bred as previously described (27)with 
sActRIIB injections given from 7 weeks of age until 16 
weeks. 
Histological analysis and immunohistochemistry 
Following dissection, testes were weighed and fixed in 
4% PFA prior to 4°C storage. PFA fixed testis were 
embedded in paraffin following a series of ethanol and 
histoclear stages. 8µm sections were cut using a Leica 
RM2155 rotary microtome prior to dewaxing in Xylene. 
Rehydration with ethanol stages was then performed 
prior to antigen retrieval in 0.01M citrate buffer pH6. 
Blocking buffer (10% FBS in TBS-Tx) was incubated on 
sections for 45 minutes at room temperature prior to 
incubation with primary antibody overnight at 4°C. 
Sections were subsequently washed in PBS-Tx three 
times prior to incubation with secondary antibody. 
Secondary antibodies attached to a fluorophore were 
used for detection of all antibodies except PLZF and 
PCNA which were detected using the Vectastain ABC-
HRP kit with a Vector NOVARed HRP substrate. All 
primary antibodies being detected were subsequently 
incubated with a secondary antibody for 1hour at room 
temperature prior to detection. Details of primary and 
secondary antibodies are given in Table 1. 
Hematoxylin and eosin 
Teste sections were dewaxed in xylene prior to 
rehydration in ethanol stages. Harris hematoxylin 
solution (Sigma HHS16) was then incubated on the slides 
for 2 minutes prior to acidic alcohol and tap water for 
blueing. Eosin solution (Sigma-Aldrich 318906) was 




Species Dilution Supplier 
PCNA Mouse 1:200 Cell signalling Technology #25865 
PLZF (D-9) Mouse 1:250 Santa Cruz Biotechnology #sc-28319 
Stra8 Rabbit 1:1000 Abcam ab49405 
Sox9 Rabbit 1:1000 Abcam ab185966 




Rabbit 1:1000 Cell signalling Technology #8828 
Smad2/Smad3 Rabbit 1:1000 Cell signalling Technology #3102 
Phospho-AKT (Ser473) Rabbit 1:1000 Cell signalling Technology #4060 
AKT Rabbit 1:1000 Cell signalling Technology #9272 
Phospho-p44/42 MAPK 
(Erk1/2) (Thr202/Tyr204) 
Rabbit 1:1000 Cell signalling Technology #9101 
p44/42 MAPK (Erk1/2) Rabbit 1:1000 Cell signalling Technology #4695 
Alpha-tubulin Mouse 1:1000 Cell signalling Technology #3873s 
 
Secondary antibodies Species Dilution Supplier 
AlexaFluor 488 anti-mouse Goat 1:200 Invitrogen 
Rabbit anti mouse IgG HRP Rabbit 1:200 DAKO #PO260 
Goat anti-rabbit IgG HRP Goat 1:5000 ThermoFisher scientific #65-6120 
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incubated on sections for 2 minutes prior to dehydration 
in ethanol and clearing with xylene. Slides were mounted 
with a coverslip and DPX mounting media. 
TM4 Sertoli cell line analysis 
In 24 well plate dishes approximately 70,000 TM4 cells 
were seeded per well. Cells were allowed to attach to the 
bottom of the dish for approximately 12 hours in cultured 
media (DMEM/F12-Gibco 11330032- supplemented 
with 10% FBS and 100Units/mL Penicillin 100ug/mL 
Streptomycin). After the 12 hours, culture media was 
supplemented with either 10ng/mL Activin A, 10ng/mL 
GDF8 or 10ng/mL GDF11. After 1 hour of 
supplementation, cell nuclei were stained with Nuc-Blue 
Life cell dye (Invitrogen) and images acquired on a Leica 
inverted microscope with UV filter. After 24 hour of 
culture cells were fixed with 4% PFA pH7.4 stained with 
DAPI and imaged on a Leica upright microscope. Cells 
were counted using the particle analysis function 
incorporated on public domain image analyses software 
Fiji. TM4 cells similarly treated for 15min were collected 
to prepare protein lysates as described below. 
Testis Protein Lysate Preparation and Western Blotting 
Frozen tissues were homogenized in detergent-free lysis 
buffer (50mM Tris pH 7.5, 150mM NaCl, 1mM 
Na3VO4, 1mM NaF, 1mM MgCl2) using a tissue 
grinder. These tissue lysates were then adjusted to 0.5% 
Triton X-100, 0.5% NP40 and incubated on ice for 15 
minutes with intermittent mixing. TM4 cells were 
collected and directly lysed in lysis buffer as above but 
also containing 0.5% TritonX-100 and 0.5% NP40 and 
incubated on ice for 15 min with intermittent mixing. 
Lysates were clarified by centrifugation at 500g and 
protein content estimated by Bradford assay (Bio-Rad, 
Hercules, CA, USA). Protein western blotting was 
performed using standard techniques. Briefly, 100μg 
lysates were separated on 10% acrylamide gels and then 
transferred to nitrocellulose membranes (Amersham 
Biosciences, Piscataway, NJ, USA). Membranes were 
washed in TBST (50mM Tris pH7.5, 150mM NaCl, 
0.05% Tween 20) and incubated with blocking buffer 
(5% non-fat dry milk in TBST) at room temperature for 
1 hour. Protein blots were incubated with primary 
antibodies, used at 1:1000 in blocking buffer, overnight 
at 4oC. Membranes were then washed three times with 
TBST and incubated with appropriate horseradish 
peroxidise conjugated secondary antibodies (Sigma, St. 
Louis, MO, USA). The membranes were again washed 
four times and the immunoblot was visualized by ECL 
(Amersham Biosciences, Piscataway, NJ, USA). 
Immunoreactive protein bands were analyzed using the 
public domain Image J program. Blots were stripped and 
reprobed with additional antibodies using standard 
methods. Briefly, stripping buffer (62.5mM Tris pH6.8, 
2% SDS, 100mM β-mercaptoethanol) was pre-heated to 
50OC in a water bath and membranes were placed into 
containers containing 100ml stripping buffer and left to 
incubate at 50oC for 40 minutes with gentle shaking. 
After membranes were removed from stripping buffer, 
they were washed extensively in TBST. Membranes were 
subsequently blocked again in 5% milk block for 1 hour 
before additional primary antibodies were applied. 
Statistical analysis 
Data are presented as mean +/- SE. Significant 
differences between two groups were performed by the 
Student’s t-test for independent variables. Normal 
distribution of data was first determined. Thereafter one-
way analysis of variance followed by Bonferroni’s 
multiple comparison tests was used for statistical 
differences between groups of more than two. Statistical 
analysis was performed on GraphPad Prism 5 with 
statistically significant differences considered at P<0.05. 
Results 
Acute impact of attenuation of Activin Receptor IIB 
signalling on the development of skeletal muscle and the 
testis 
Inhibiting ligand binding to the Activin Receptor IIB has 
been demonstrated in a number of differing contexts to 
induce muscle growth in adult mice.27-29 Here we 
examined the outcome of exposing very young mice. 
This is a period of development akin to the proposed 
optimum window for treating boys with DMD, to the 
soluble form of the Activin type IIB receptor (sActRIIB), 
which has been previously shown to prevent both Activin 
and Myostatin from binding to their receptor. Mice were 
injected twice weekly through the intraperitoneal route 
from p17 to p35 and culled at p37 (Fig. 1A). The body 
weights were not significantly changed by sActRIIB 
treatment (Fig. 1B). In contrast all the muscles examined 
had increased in weight, exemplified by the 20% increase 
in gastrocnemius mass (Fig. 1C). During the course of 
tissue recovery, we noticed that the testis were smaller in 
the sActRIIB treated group compared to those receiving 
vehicle (PBS) (Fig. 1D). The testis from the sActRIIB 
cohort were also smaller when their weight was 
expressed as a ratio to body weight (data not shown). We 
investigated the underlying cellular cause for the 
decreased testis weight through histological and 
immunocytochemical investigations. Individual 
seminiferous tubules were readily identifiable in both 
cohorts with expected peritubular, basal, adluminal 
cellular distribution and lumen. The tubule diameters 
from sActRIIB treated mice, however, were significantly 
smaller after sActRIIB treatment compared to controls 
(Fig. 1, E and H). Lumen area was smaller in sActRIIB 
treated samples than those of controls but did not reach 
statistical significance (Fig. 1F). Finally the area of the 
cellular component of each tubule was measured and 
revealed that this parameter was lower in sActRIIB 
treated samples compared to controls (Fig. 1G). These 
findings suggest a reduction of spermatogenesis upon 
sActRIIB treatment. We then sought to elucidate whether 
sActRIIB treatment led to alterations in cellular 
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distribution or processes in the testis that might cause a 
likely reduction in spermatogenesis. 
SActRIIB treatment decreases proliferation of cells in the 
testis of young mice 
To assess whether the reduction of seminiferous tubule 
cross section is caused by reduced cell proliferation we 
quantified the number of proliferating cell nuclear 
antigen (PCNA) expressing cells. While the location of 
proliferating cells, adjacent to the basement membrane 
did not differ, there were significantly fewer proliferating 
cells in the tubules of sActRIIB treated samples than 
controls (Fig. 1, I and M). Since proliferating cells, A and 
B type spermatogonial cells, within tubules originate 
 
Fig 1.  sActRIIB causes a reduction in testicular development in young CD1 mice. (A) Schematic of experimental design. Black arrows injection 
of 10mg/kg sActRIIB. Red arrows indicate time of cull. (B) Body weight at P37. (C) Gastrocnemius mass. (D) Teste mass. (E) Average 
tubule area. (F) Average lumen area. (G) Average differentiation thickness. (H) H&E of seminiferous tubule in PBS & sActRIIB treated 
showing smaller tubule with sActRIIB. (I) PCNA positive cells in PBS & sActRIIB tubules showing a reduction in sActRIIB tubule. (J) 
PLZF positive cells in PBS & sActRIIB tubules. (K) Stra8 positive cells in PBS & sActRIIB tubules. (L) Sox9 positive cells in PBS & 
sActRIIB tubules. (M) Quantification of PCNA positive cells per tubule. (N) Quantification of PLZF positive cells per tubule. (O) 
Quantification of Stra8 positive cells per tubule. (P) Quantification of Sox9 positive cells per tubule. n=5 PBS treated male mice, n=6 
sActRIIB treated male mice. Scale for all images represents 50µm. Student’s t-Test used for statistical significance. *p<0.05, **<0.01, 
***<0.001. H&E, haematoxylin & eosin; PCNA, proliferating cell nuclear antigen; PLZF, promyelocytic leukemia zinc finger; Stra8, 
Stimulated By Retinoic Acid 8; Sox9, SRY-Box 9. 
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from spermatogonial stem cells (SSC) we quantified the 
SSC population using PLZF immunostaining,30 and 
found that sActRIIB treatment did not affect 
spermatogonial stem cell number per tubule (Fig. 1, J and 
N) or the ability of preleptotene spermatocyte to enter 
meiosis as demonstrated in Fig. 1, K and O by Stra8 
staining.31 Lastly we quantified the number of Sertoli 
cells, identified by Sox9 expression,32 which supports 
and thus ultimately limits the extent of spermatogenesis 
in each tubule and found no differences in this parameter 
between the sActRIIB treated group and controls (Fig. 1, 
L and P). Importantly, at this time point we did not see 
evidence of sperm tails either through H - E staining or 
immunostaining with sperm tail specific markers,33 
including Aquaporin3 (Fig. 1H and data not shown). 
Of note, there was no effect on Leydig cell numbers by 
sActRIIB treatment (data not shown). 
 
Fig 2. sActRIIB causes a reduction in testes weight and tubule areas at P56 in CD1 mice. (A) Schematic of experimental design. Black arrows 
show injection of 10mg/kg sActRIIB. Red arrows indicate time of cull. (B) Body weight at P56. (C) Gastrocnemius mass. (D) Teste mass. 
(E) Average tubule area. (F) Average lumen area. (G) Average differentiation thickness. (H) H&E of seminiferous tubule in PBS & 
sActRIIB treated showing smaller tubule with sActRIIB. (I) PCNA positive cells in PBS & sActRIIB tubules showing a reduction in 
sActRIIB tubule. (J) PLZF positive cells in PBS & sActRIIB tubules. (K) Stra8 positive cells in PBS & sActRIIB tubules. (L) Sox9 positive 
cells in PBS & sActRIIB tubules. (M) AQP3 positive tubules. (N) Quantification of PCNA positive cells per tubule. (O) Quantification of 
PLZF positive cells per tubule. (P) Quantification of Stra8 positive cells per tubule. (Q) Quantification of Sox9 positive cells per tubule. 
(R) Quantification of AQP3 positive tubules as a percentage of total tubules. n=5 PBS treated male mice, n=5 sActRIIB treated male 
mice. Scale for all images represents 50µm. Student’s t-Test used for statistical significance. *p<0.05, **<0.01, ***<0.001. H&E, 
haemotoxylin & eosin; PCNA, proliferating cell nuclear antigen; PLZF, promyelocytic leukemia zinc finger; Stra8, Stimulated By 
Retinoic Acid 8; Sox9, SRY-Box 9. 
 
Inhibition of Activin/Myostatin signalling impairs mouse testis 
Eur J Transl Myol 30 (1): 62-78, 2020 
- 68 - 
 
sActRIIB decreases sperm number 
 The data from examining the testis of p37 mice 
demonstrated that sActRIIB, while promoting muscle 
growth, prevented them from developing to their normal 
size. While testicular cell proliferation was reduced in 
mice treated with sActRIIB in the prepubertal stage, we 
wanted to investigate whether this affects sperm 
production in the adult. To that end we carried out the 
same experiment as outlined in Figure 1 except that mice 
were culled at p56 (adult) since sperm are not fully 
matured in mice at p37. Examination of body weights of 
mice treated from p17 to p35 and left for another 21 days 
(to p56) showed that the sActRIIB treated groups were 
heavier (23%) than those injected with PBS (Fig. 2, A 
and B). Although the gastrocnemius muscle in the 
sActRIIB group had increased in weight (by 56%), the 
testes were lighter (by 19%) than those of controls (Fig. 
2, C and D). Similar to the P37 mice, the cross-section of 
the seminiferous tubules from treated mice were smaller 
which was quantitatively verified to show a decrease in 
 
 
Fig 3. sActRIIB causes a reduction in testes weight and tubule areas at P56 in C57/B10 mice. (A) Schematic of experimental design. Black 
arrows injection of 10mg/kg sActRIIB. Red arrows indicate time of cull. (B) Body weight at P56. (C) Gastrocnemius mass. (D) Teste 
mass. (E) Average tubule area. (F) Average lumen area. (G) Average differentiation thickness. (H) H&E of seminiferous tubule in PBS 
& sActRIIB treated showing smaller tubule with sActRIIB. (I) PCNA positive cells in PBS & sActRIIB tubules showing a reduction in 
sActRIIB tubule. (J) PLZF positive cells in PBS & sActRIIB tubules. (K) Stra8 positive cells in PBS & sActRIIB tubules. (L) Sox9 positive 
cells in PBS & sActRIIB tubules. (M) AQP3 positive tubules. (N) Quantification of PCNA positive cells per tubule. (O) Quantification of 
PLZF positive cells per tubule. (P) Quantification of Stra8 positive cells per tubule. (Q) Quantification of Sox9 positive cells per tubule. 
(R) Quantification of AQP3 positive tubules as a percentage of total tubules. n=5 PBS treated male mice, n=5 sActRIIB treated male 
mice. Scale for all images represents 50µm. Student’s t-Test used for statistical significance. *p<0.05, **<0.01, ***<0.001. H&E, 
haematoxylin & eosin; PCNA, proliferating cell nuclear antigen; PLZF, promyelocytic leukaemia zinc finger; Stra8, Stimulated By 
Retinoic Acid 8; Sox9, SRY-Box 9. 
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tubule area, lumen area and thickness of spermatogenic 
area in sActRIIB treated samples (Fig. 2, E-H). Again, 
like the p37 experiment, the number of proliferating cells 
was decreased in sActRIIB samples (Fig. 2, I and N) but 
there was no change in the density of PLZF, Stra8 and 
Sox9 positive cells (Fig. 2, I-L and O-Q). By p57, 
however, the control cohort contained matured 
spermatozoa, as evidenced by tails marked by aquaporin 
3, in the seminiferous tubule lumen which was very 
significantly reduced in sActRIIB treated samples (Fig. 
2, M and R). 
We examined whether genetic background was a 
modifying factor in terms of tissue response to exposure 
to sActRIIB. We carried out a series of experiments using 
C57Bl10 (Fig. 3) as well as the FVB (data not shown) 
background. In both strains, injection of sActRIIB at p17 
 
Fig 4. sActRIIB causes a reduction in tubule areas at P180. (A) Schematic of experimental design. Black arrows injection of 10mg/kg sActRIIB. 
Red arrows indicate time of cull. (B) Body weight at P180. (C) Gastrocnemius mass. (D) Teste mass. (E) Average tubule area. (F) 
Average lumen area. (G) Average differentiation thickness. (H) H&E of seminiferous tubule in PBS & sActRIIB treated showing smaller 
tubule with sActRIIB. (I) PCNA positive cells in PBS & sActRIIB tubules showing a reduction in sActRIIB tubule. (J) PLZF positive cells 
in PBS & sActRIIB tubules. (K) Stra8 positive cells in PBS & sActRIIB tubules. (L) Sox9 positive cells in PBS & sActRIIB tubules. (M) 
AQP3 positive tubules. (N) Quantification of PCNA positive cells per tubule. (O) Quantification of PLZF positive cells per tubule. (P) 
Quantification of Stra8 positive cells per tubule. (Q) Quantification of Sox9 positive cells per tubule. (R) Quantification of AQP3 positive 
tubules as a percentage of total tubules. n=5 PBS treated male mice, n=5 sActRIIB treated male mice. Scale for all images represents 
50µm. Student’s t-Test used for statistical significance. *p<0.05, **<0.01, ***<0.001. H&E, haemotoxylin & eosin; PCNA, 
proliferating cell nuclear antigen; PLZF, promyelocytic leukemia zinc finger; Stra8, Stimulated y Retinoic Acid 8; Sox9, SRY-Box 9. 
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to p35 followed by tissue isolation at p56 (Fig. 3A) 
resulted in robust muscle mass increase (Fig. 3B) and a 
decrease in testis weight (Fig. 3C). Again there was a 
decrease in tubule area, lumen area as well as 
differentiation area (Fig. 3D-F). As for the CD1 
background, immunocytochemical studies revealed a 
decrease in the number of PCNA and AQP3 containing 
tubules without any significant changes in PLZF, Stra8 
or Sox9 levels (Fig. 3G-Q). 
Therefore, treatment of young mice with sActRIIB 
results in sustained increased skeletal muscle levels but 
smaller testis which (at least for the CD1 strain) 
contained less than the normal number of mature 
spermatozoa. 
sActRIIB treatment in young mice results in long term 
testicular abnormalities 
We then investigated whether the reduced 
spermatogenesis in adult mice caused by a cellular 
proliferation defect resulting from sActRIIB treatment of 
pre-pubertal mice, was of a permanent nature or whether 
this effect was reversible. To that end we injected mice 
until p35 and examined tissues at p180 (Fig. 4, A-R). 
Here we failed to detect any significant difference in 
 
Fig. 5 sActRIIB causes a reduction in testes weight and tubule areas when administered in fully developed adult mice. (A) Schematic of 
experimental design. Black arrows injection of 10mg/kg sActRIIB. Red arrows indicate time of cull. (B) Body weight at P112. (C) 
Gastrocnemius mass. (D) Teste mass. (E) Average tubule area. (F) Average lumen area. (G) Average differentiation thickness. (H) H&E 
of seminiferous tubule in PBS & sActRIIB treated showing smaller tubule with sActRIIB. (I) PCNA positive cells in PBS & sActRIIB 
tubules showing a reduction in sActRIIB tubule. (J) PLZF positive cells in PBS & sActRIIB tubules. (K) Stra8 positive cells in PBS & 
sActRIIB tubules. (L) Sox9 positive cells in PBS & sActRIIB tubules. (M) AQP3 positive tubules. (N) Quantification of PCNA positive 
cells per tubule. (O) Quantification of PLZF positive cells per tubule. (P) Quantification of Stra8 positive cells per tubule. (Q) 
Quantification of Sox9 positive cells per tubule. (R) Quantification of AQP3 positive tubules as a percentage of total tubules. n=4 PBS 
treated male mice, n=4 sActRIIB treated male mice. Scale for all images represents 50µm. Student’s t-Test used for statistical 
significance. *p<0.05, **<0.01, ***<0.001. H&E, haemotoxylin & eosin; PCNA, proliferating cell nuclear antigen; PLZF, 
promyelocytic leukemia zinc finger; Stra8, Stimulated By Retinoic Acid 8; Sox9, SRY-Box 9; AQP3, Aquaporin 3. 
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body, muscle or testis weight between the two cohorts. 
However examination of testis still showed that the 
sActRIIB cohort displayed lower tubule area and 
differentiation area compared to the PBS treated mice. 
Additionally the sActRIIB cohort contained fewer 
spermatozoa as quantified through AQP3 staining 




Fig 6. sActRIIB causes a reduction in testes weight and tubule areas in Ercc1∆/- treated mice. (A) Schematic of experimental design. Black 
arrows injection of 10mg/kg sActRIIB. Red arrows indicate time of cull. (B) Body weight at P112. (C) Gastrocnemius mass. (D) Teste 
mass. (E) Average tubule area. (F) Average lumen area. (G) Average differentiation thickness. (H) H&E of seminiferous tubule in PBS 
& sActRIIB treated showing smaller tubule with sActRIIB. (I) PCNA positive cells in PBS & sActRIIB tubules showing a reduction in 
sActRIIB tubule. (J) PLZF positive cells in PBS & sActRIIB tubules. (K) Stra8 positive cells in PBS & sActRIIB tubules. (L) Sox9 positive 
cells in PBS & sActRIIB tubules. (M) AQP3 positive tubules. (N) Quantification of PCNA positive cells per tubule. (O) Quantification of 
PLZF positive cells per tubule. (P) Quantification of Stra8 positive cells per tubule. (Q) Quantification of Sox9 positive cells per tubule. 
(R) Quantification of AQP3 positive tubules as a percentage of total tubules.  n=4 PBS treated male mice, n=4 PBS treated Ercc1∆/- 
male mice, n=5 sActRIIB treated Ercc1∆/- male mice. Scale for all images represents 50µm. One-way ANOVA followed by Bonferroni’s 
multiple comparison tests, *p<0.05, **<0.01, ***<0.001. H&E, haematoxylin & eosin; PCNA, proliferating cell nuclear antigen; PLZF, 
promyelocytic leukemia zinc finger; Stra8, Stimulated By Retinoic Acid 8; Sox9, SRY-Box 9; AQP3, Aquaporin 3. 
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sActRIIB induces testis atrophy in adult mice and in 
model of aged mice 
The experiments conducted thus far were initiated in 
young mice. We next determined the consequence of 
sActRIIB treatment on adult mice as well as in a model 
of extreme ageing. In the first set of these experiments, 
adult mice (p56) were treated until p110 and thereafter 
culled at p112 (Fig. 5, A-R). sActRIIB treated mice 
showed a non-significant increase in body weight but a 
significant increase in muscle weight compared to 
controls (Fig. 5, B-C). In contrast, the testis were lighter 
in the sActRIIB group compared to controls (Fig. 5, D). 
The sActRIIB group showed non-significant decrease in 
tubule area, lumen area as well as differentiation area 
(Fig. 5, E-G). Nevertheless PCNA counts were lower in 
the sActRIIB group (Fig. 5, N) as were the number of 
tubules containing AQP3 positive spermatozoa (Fig. 5, 
R).  
Thereafter we examined the consequence of sActRIIB 
treatment on the ErccΔ/- mice, an established mouse 
model of ageing.34 Mice were injected from p56 (before 
 
Fig. 7. Testes weight and tubule areas are reduced in Mstn heterozygous and Mstn null mice. (A) Body weight at 7.5 months. (B) Teste mass. 
(C) Average tubule area. (D) Average lumen area. (E) Average differentiation thickness. (F) H&E of seminiferous tubule in PBS & 
sActRIIB treated showing smaller tubule with sActRIIB. (G) PCNA positive cells in PBS & sActRIIB tubules showing a reduction in 
sActRIIB tubule. (HJ) PLZF positive cells in PBS & sActRIIB tubules. (I) Stra8 positive cells in PBS & sActRIIB tubules. (J) Sox9 positive 
cells in PBS & sActRIIB tubules. (K) AQP3 positive tubules. (L) Quantification of PCNA positive cells per tubule. (M) Quantification of 
PLZF positive cells per tubule. (N) Quantification of Stra8 positive cells per tubule. (O) Quantification of Sox9 positive cells per tubule. 
(P) Quantification of AQP3 positive tubules as a percentage of total tubules.  n=4 PBS treated male mice, n=5 Mstn+/- male mice, n=4 
Mstn-/- male mice. Scale for all images represents 50µm. One-way ANOVA followed by Bonferroni’s multiple comparison tests, *p<0.05, 
**<0.01, ***<0.001. H&E, haematoxylin & eosin; PCNA, proliferating cell nuclear antigen; PLZF, promyelocytic leukemia zinc finger; 
Stra8, Stimulated By Retinoic Acid 8; Sox9, SRY-Box 9 
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signs of overt ageing) and tissues collected at p112 a time 
point which we have previous shown to be equivalent of 
over 2.5 mouse years (Fig. 6A).27 Progeric mice 
displayed lower body weights compared to controls at 
p112 (Fig. 6B). sActRIIB treatment of progeric mice 
resulted in a non-significant increase in body weight (Fig. 
6B) accompanied by an increase in muscle mass albeit 
not reaching control levels (Fig. 6C). In contrast, testis 
weights were lowered in ErccΔ/- mice by sActRIIB (Fig. 
6D). Tubule area, lumen area as well as differentiation 
thickness was smaller in ErccΔ/- testis compared to 
controls which reduced further following the treatment of 
ErccΔ/- mice with sActRIIB (Fig. 6, E-G). 
Immunocytochemical analysis revealed crucial interplay 
between progeric mechanisms and inhibition of TGF 
signalling in the ErccΔ/- mice. Whereas levels of 
proliferating cells, number of cells undergoing meiosis 
and mature spermatozoa were lower in the ErccΔ/- tissue 
compared to controls, there was no difference between 
these cohorts in terms of the number of primary germ 
cells or Sertoli cells (Fig. 6, H-R). Treatment of ErccΔ/- 
mice with sActRIIB resulted in a significant decrease in 
PCNA and AQP3 containing tubules and a non-
significant reduction in Sertoli cell number. Most 
interestingly, sActRIIB treatment lead to almost a 
complete downregulation of AQP3 in ErccΔ/- testes 
resulting in a total elimination of the sperm production. 
 
 
Fig 8. Differential effects of TGF ligands on TM4 Sertoli cell proliferation and signalling. (A) Fold increase in the number of cells over 24h. 
(B) Immunoblot analyses of TM4 lysates that were either untreated or treated with 10ng/ml of indicated ligands for 15min for either 
phosphorylated or total target proteins (AKT, Smad2/3 and ERK) as indicated. (C) Bar graphs representing densitometric quantification 
of phosphorylated target protein normalised to total target protein from western blotting experiments shown in (B). Student’s t-Test used 
for statistical significance. n = 3, **p<0.01. 
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These experiments show that when prepubertal mice are 
treated with sActRIIB, there is a strong reduction of 
cellular proliferation which leads to reduced 
spermatogenesis later in life. This treatment however 
does not affect the resident spermatogonial stem cell 
population or their ability to enter meiosis. Further, this 
effect is not permanent and there is a modest recovery 
leading to sperm production later in life. Moreover, 
sActRIIB treatment at any stage in the life of a mouse is 
likely to decreases testis size and spermatogenesis. 
Crucially we have also identified an interaction between 
TGF signalling and ageing of the testis in that sActRIIB 
treatment synergizes with progeroid signalling to prevent 
germ cell entry into meiosis  
sActRIIB induces testicular side-effects in Myostatin null 
mice 
Our work shows that attenuation of signalling through the 
ActRIIB can lead to decreased testis mass. One of the 
molecules that promotes muscle mass through this 
receptor is Myostatin. To our knowledge a testicular 
phenotype has not been reported in Myostatin null mice 
but as a consequence of the results of this study, we 
examined both the heterozygous and null Myostatin 
variants. We found that both the heterozygous and 
homozygous Myostatin mutants had lower testis weights 
compared to WT litter mates (Fig. 7, A-B). The testis 
from the nulls were lighter than those from heterozygous 
mice but failed to reach statistical significance. 
Histological examination of the tissue revealed that both 
the heterozygous and null mice had decreased tubule, 
lumen and differentiation areas compared to WT litter 
mates (Fig. 7, C-F). Immunocytochemical studies 
revealed a decrease in the number of AQP3 containing 
tubules without any significant changes in PCNA, PLZF, 
Stra8 or Sox9 levels (Fig. 7, G-P). 
Postnatal Sertoli cell numbers are regulated by FSH, IGF, 
testosterone, and Activin action. Since sActRIIB can 
inhibit Activin, Myostatin and GDF11 action, we 
addressed whether these ligands affect cellular 
proliferation in a Sertoli cell line, TM4. As shown in Fig. 
8, A, only Activin induces TM4 cellular proliferation and 
not Mstn or GDF11. Importantly, when investigating 
proximal signalling effects of these three ligands on TM4 
we found only Activin to significantly induce both 
Smad2 and AKT activation (Fig. 8, B and C). The lack of 
any effect of sActRIIB treatment on Sertoli cell numbers 
in vivo might be due to the fact that the injection regime 
started at p17, and Sertoli cell proliferation is known to 
occur up to p15 in mice.36 Since Myostatin does not 
induce Smad2 phosphorylation in TM4 cells (Fig. 8, B 
and C), yet show a similar phenotype as that of mice 
treated with sActRIIB and since sActRIIB might not 
traverse the blood testis barrier, it is likely that the 
constellation of testicular defects described in this study 
might be due to the reduced effect of Activin and 
Myostatin action on cells of the spermatogonial lineage. 
Crucially, however Activin inhibition appears to affect 
cells up to the primary spermatocytes, whereas the effect 
of Myostatin deletion is seen only in later stages. 
Discussion 
ACE-031, a molecule similar to the sActRIIB used in this 
study, was progressed into a phase II clinical trial on boys 
with DMD. However the study was stopped due to safety 
concerns related to epitaxis and telangiectasias.37 
Previous work has reported that a similar molecule to 
ACE-031 and sActRIIB used in our study induced side 
effects related to the spleen and pancreas.21 In this study 
we hypothesized that testis development may be affected 
by sActRIIB given the important role that Activin has on 
this organ. Our study shows that sActRIIB promotes 
robust muscle growth in a matter of 20 days in mice. 
However this was accompanied by a decrease in testis 
weight. This effect was independent to the genetic 
background of mice, since here we examined three 
routinely used strains (CD-1, C57/Bl10 and FVB). 
Examination of testicular structure showed that sActRIIB 
inhibited the proliferation of cells in testis without 
impacting on the number of germ cells, undergoing 
meiosis or Sertoli cells. We show that following 
cessation of sActRIIB treatment, the rate of muscle 
growth in treated mice is reduced compared to untreated 
mice such that by 145 days after last treatment both the 
treated and untreated mice have the same muscle mass 
(Figure 4). Importantly, although the muscle phenotype 
induced by sActRIIB treatment has been erased at this 
time, the testis phenotype has not. These results show that 
positive outcomes of sActRIIB treatment are shorter 
lived than that detrimental impact on the testis.  
Importantly, we show that both mature wild-type mice an 
ageing model undergo muscle hypertrophy and testicular 
atrophy following sActRIIB treatment. The most 
pronounced impact of the treatment in terms of potential 
testicular function was in fact in the model of aged mice 
where sActRIIB totally eliminated the formation of 
AQP3 positive sperm. We believe that the side effects 
detected after the application of sActRIIB at any stage of 
life is highly relevant since therapies based on attenuating 
Myostatin/Activin function are being developed for 
juvenile (e.g. DMD)38,39 adult (heart failure)39, and late 
onset diseases, e.g. inclusion body myositis, 
oculopharyngeal muscular dystrophy,40,41 as well as 
sarcopenic obesity.42 
The data from our study regarding the inhibition of testis 
development can be explained by on-target effects that 
should be expected for a molecule that inhibits Activin.45 
It is surprising that, to the best of our knowledge, a testis 
phenotype has not been described in other studies using 
similar molecules which bring about muscle growth. In 
many studies there is no mention that the testis were 
examined and even when they were, there is not data 
presented regarding their mass.46-47 It is also not clear 
whether testicular size was examined in boys on the 
ACE-083 trial. However, we suggest that in future this 
metric be included in any clinical trial that relies on 
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Myostatin/Activin neutralization as the mode of action to 
promote muscle growth. 
Although both sActRIIB treatment of wild-type mice and 
Myostatin deletion shows a reduction of spermatogenesis 
in mice, the mechanism of pathogenesis is likely to be 
different. Although Activin is known to play crucial local 
roles in both the pituitary and the ovary, sActRIIB 
treatment does not affect the ovarian cycle in mice (not 
shown) suggesting that the working of the hypothalamus-
pituitary-gonad (HPG) axis is intact even in the presence 
of a circulating inhibitor of Activin. Given this, therefore, 
it is not expected that sActRIIB treatment affects 
pituitary function in the male. Contrasting the ovary, 
however, testicular function of spermatogenesis is 
strongly affected by sActRIIB most likely due to the 
abrogation of Activin action on the spermatogenic cells 
themselves. Removal of sActRIIB treatment restores 
spermatogenesis supporting a partially reversible nature 
of this brake on the process. This reversibility is expected 
since sActRIIB treatment does not affect SC or germ cell 
numbers. Contrasting from the Mstn-/- mouse testis, 
however, there is a clear reduction of PCNA positive 
cells close to the basement membrane inside the 
seminiferous tubule upon sActRIIB treatment. This is 
indicative of reduction of spermatogonial proliferation 
which then suggests that the reduction of testicular size 
and function in the injected model is due to early 
inhibition of spermatogenesis. The effectiveness of 
sActRIIB as a modulator of Activin function, 
demonstrated by the reduction of Smad2 activation, 
provides a possible therapeutic strategy to alleviate 
testicular seminoma development. It has been shown that 
when gonocyte differentiation to spermatogonia is 
compromised, the gonocytes produce cancer in-situ or 
CIS cells within the testis.45 These cells develop into 
seminoma or non-seminoma origin cancers. Importantly, 
at every stage of the differentiation of the gonocyte to 
testicular cancer Smad2/3 activation appears to be a 
common factor. This activation might be effectively 
contained or inhibited by sActRIIB treatment. 
In addition to effects on the testis, it is likely that the 
ligand trap might affect Activin action elsewhere in the 
body in a context-dependent manner. While 
angiogenesis, liver and kidney function might also be 
affected, a pronounced behavioral effect is also expected 
upon sActRIIB injection. There is clear evidence of 
ActRIIB expression in the amygdala indicating that 
Activin might play a role in anxiety-type Behaviour. 
Moreover, it is known that the presence of Activin has a 
calming effect on the afferents from the amygdala 
whereas absence or reduction of Activin can lead to 
aggressive Behaviour stemming from heightened 
anxiety. In support of this, we have found that sActRIIB 
treated male mice show highly aggressive Behaviour (not 
shown). Our sActRIIB injection protocol, therefore, 
presents a model system to further investigate behavioral 
issues such as anxiety and anxiety-related aggression.  
Our study details an experimental intervention in mice 
that leads to the development of muscularity but at the 
same time induces testicular atrophy. A similar outcome 
has been described in men who abuse androgenic 
anabolic steroids.53,54 The co-presentation of these two 
traits in an organism are in conflict when viewed from 
evolutionary fitness perspective as big muscles in men 
are deemed indicative of high genetic quality and positive 
factors in mate selection by women.55 This scenario is 
called the Mossman-Pacey Paradox which can be 
succinctly summarized as representing a conflict between 
masculinity and muscularity.56 It is important to 
recognize that muscle mass increase induced through 
abuse of androgenic anabolic steroid is also associated 
with a list of other undesirable health issues including 
acne, gynaecomastia and most importantly mortality.53 
Future work will investigate these features in our mouse 
model of muscle growth induced by sActRIIB. Most 
importantly the work presented here should be taken as a 
warning sign for those who want to use 
Myostatin/Activin inhibitors for vanity purposes. 
In summary, we demonstrate that attenuation of 
Myostatin/Activin signalling delivers significant muscle 
growth at any stage in the life of a rodent. However, 
sActRIIB injection induced an abnormal testis phenotype 
at any stage of the rodent’s life. The functional 
consequence of the decrease testis size may impact on 
fertility. Future work will investigate fertility of mice that 
have been treated with sActRIIB. Furthermore we will 
investigate in an appropriately timed manner the role this 
molecule plays on female reproductive organs. 
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